ERBB2 and breast carcinoma: Adjuvant endocrine therapy is a mainstay of treatment for the 70% of breast cancer patients whose breast cancer expresses Estrogen Receptors (ER) and/or Progesterone Receptors (PR) but not HER2 [3].